Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Madrigal Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MDGL
Nasdaq
2834
https://www.madrigalpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Madrigal Pharmaceuticals Inc
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
- Mar 26th, 2024 1:53 pm
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
- Mar 22nd, 2024 10:15 am
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
- Mar 19th, 2024 9:50 am
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
- Mar 19th, 2024 3:58 am
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
- Mar 19th, 2024 12:01 am
Madrigal Pharmaceuticals Announces Proposed Public Offering
- Mar 18th, 2024 8:04 pm
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark
- Mar 18th, 2024 7:15 pm
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
- Mar 18th, 2024 11:00 am
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
- Mar 17th, 2024 9:50 am
Wegovy and Zepbound Cast Shadow Over Madrigal’s Liver Drug
- Mar 15th, 2024 8:35 pm
Madrigal Stock Soars 11% After FDA Approved The First MASH Treatment
- Mar 15th, 2024 8:14 pm
Geron, Madrigal Pharmaceuticals jump on good news from FDA
- Mar 15th, 2024 7:50 pm
Madrigal Pharmaceuticals Stock Surges After FDA Approves Liver Disease Treatment
- Mar 15th, 2024 6:34 pm
US STOCKS-Wall St slides as inflation woes dampen rate-cut bets
- Mar 15th, 2024 4:09 pm
Madrigal Can Market the First Drug for Obesity-Scarred Livers. The Stock Soars.
- Mar 15th, 2024 2:01 pm
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
- Mar 15th, 2024 1:30 pm
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
- Mar 15th, 2024 9:35 am
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
- Mar 14th, 2024 8:15 pm
Madrigal wins FDA approval of first drug for MASH
- Mar 14th, 2024 4:11 pm
Scroll